Across TCGA pan-cancer cohorts, RN7SL339P RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RN7SL339P’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where RN7SL339P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RN7SL339P is over-expressed in tumor.
PRAD and LUSC are the cancer types where RN7SL339P tumor–normal differential expression is most reproducible.